<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORTOMYCIN- neomycin sulfate, polymyxin b sulfate, bacitracin zinc and hydrocortisone ointment </strong><br>Major Pharmaceuticals<br></p></div>
<h1>Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Ophthalmic Ointment, USP<br>(Sterile) </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_de9da512-b568-4b94-a7c8-4e41e950ae65"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Ophthalmic Ointment, USP is a sterile antimicrobial and anti-inflammatory ointment for ophthalmic use.</p>
<p><span class="Bold">Each Gram Contains: </span>ACTIVES: Neomycin sulfate (equivalent to 3.5 mg neomycin base), Polymyxin B Sulfate equivalent to 10,000 polymyxin B units, Bacitracin Zinc equivalent to 400 bacitracin units, Hydrocortisone 10 mg (1%); INACTIVES: White Petrolatum, Mineral Oil.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae </span>Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis.</p>
<p>The structural formulae are:</p>
<div class="Figure"><img alt=" Neomycin Sulfate (structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c50e7f2-1208-4f19-9807-4ab0dd314d3b&amp;name=7c50e7f2-1208-4f19-9807-4ab0dd314d3b-01.jpg"></div>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span>, which are produced by the growth of <span class="Italics">Bacillus polymyxa</span> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis.</p>
<p>The structural formulae are:</p>
<div class="Figure"><img alt="Polymyxin B Sulfate (structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c50e7f2-1208-4f19-9807-4ab0dd314d3b&amp;name=7c50e7f2-1208-4f19-9807-4ab0dd314d3b-02.jpg"></div>
<p>Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the <span class="Italics">licheniformis </span>group of <span class="Italics">Bacillus subtilis </span>var Tracy. It has a potency of not less than 40 bacitracin units per mg.</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="Bacitracin Zinc (structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c50e7f2-1208-4f19-9807-4ab0dd314d3b&amp;name=7c50e7f2-1208-4f19-9807-4ab0dd314d3b-03.jpg"></div>
<p>Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone.</p>
<p>Its structural formula is:</p>
<div class="Figure"><img alt="Hydrocortisone (structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c50e7f2-1208-4f19-9807-4ab0dd314d3b&amp;name=7c50e7f2-1208-4f19-9807-4ab0dd314d3b-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_cbd8d468-f1b1-4226-8c47-f1c75efc19be"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body’s defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, concomitant antimicrobial drugs may be used when this inhibition is considered to be clinically significant in a particular case.</p>
<p>When a decision to administer both a corticosteroid and antimicrobials is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of all drugs is administered. When each type of drug is in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained.</p>
<p>The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_2cddc851-927f-4040-8fed-582eabd66b65"></a><a name="section-2.1"></a><p></p>
<h2>Microbiology: </h2>
<p class="First">The anti-infective components in neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment are included to provide action against specific organisms susceptible to it. Neomycin sulfate and polymyxin B sulfate are active <span class="Italics">in vitro </span>against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms: <span class="Italics">Staphylococcus aureus</span>, streptococci, including <span class="Italics">Streptococcus</span><span class="Italics"> pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter </span>species, <span class="Italics">Neisseria </span>species, and <span class="Italics">Pseudomonas</span><span class="Italics"> aeruginosa</span>. This product does not provide adequate coverage against <span class="Italics">Serratia marcescens </span>(see <a href="#i4i_indications_id_1d083092-5c04-4641-ae75-1ffd6c66e4c8">INDICATIONS AND USAGE</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_1d083092-5c04-4641-ae75-1ffd6c66e4c8"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a risk of <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> exists.</p>
<p>Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. They are also indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, radiation, or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>, or penetration of foreign bodies.</p>
<p>The use of a combination drug with an anti-infective component is indicated where the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see <a href="#i4i_clinical_pharmacology_id_cbd8d468-f1b1-4226-8c47-f1c75efc19be">CLINICAL PHARMACOLOGY</a>: <a href="#i4i_microbiology_id_2cddc851-927f-4040-8fed-582eabd66b65">Microbiology</a>).</p>
<p>The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: <span class="Italics">Staphylococcus</span><span class="Italics"> aureus</span>, streptococci, including <span class="Italics">Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter </span>species,<span class="Italics"> Neisseria </span>species, and <span class="Italics">Pseudomonas aeruginosa</span>. The product does not provide adequate coverage against <span class="Italics">Serratia marcescens</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_bf25d03e-25b5-4d05-8d6c-7f7aedb74957"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is contraindicated in most viral diseases of the cornea and conjunctiva including: epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures.</p>
<p>This product is also contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the antibiotic component occurs at a higher rate than for other components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_57e2715b-372b-48d4-9921-eb743e0c5fd8"></a><a name="section-5"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. Neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation.</p>
<p>Prolonged use may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. In acute purulent conditions of the eye, corticosteroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in uncooperative patients. Corticosteroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>The use of corticosteroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of filtering blebs.</p>
<p>Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). Employment of corticosteroid medication in the treatment of herpes simplex requires great caution.</p>
<p>Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Applications of products containing these ingredients should be avoided for the patient thereafter (see <a href="#i4i_precautions_id_b978d731-fca2-4276-a41c-83e5e8efbad1">PRECAUTIONS</a>: <a href="#i4i_precautions_general_id_ea317a74-50ee-43e4-881d-ef94c86c753e">General</a>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_b978d731-fca2-4276-a41c-83e5e8efbad1"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_ea317a74-50ee-43e4-881d-ef94c86c753e"></a><a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">The initial prescription and renewal of the medication order beyond 8 grams should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.</p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after prolonged corticosteroid dosing. Fungal cultures should be taken when appropriate.</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be monitored (see <a href="#i4i_warnings_id_57e2715b-372b-48d4-9921-eb743e0c5fd8">WARNINGS</a>).</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (see <a href="#i4i_info_patients_id_57b6c8de-5e44-4527-99a7-423159322cc0">PRECAUTIONS: Information for Patients</a>).</p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: kanamycin, paromomycin, streptomycin, and possibly gentamicin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_57b6c8de-5e44-4527-99a7-423159322cc0"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. The use of this product by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated products (see <a href="#i4i_precautions_general_id_ea317a74-50ee-43e4-881d-ef94c86c753e">PRECAUTIONS: General</a>).</p>
<p>If the condition persists or gets worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> develops, the patient should be advised to stop use and consult a physician. Do not use this product if you are allergic to any of the listed ingredients.</p>
<p>Keep tightly closed when not in use. Keep out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_0792a259-0bfd-4599-bf35-e8ceefb5a3c5"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin. Treatment of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro </span>with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 mcg /mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown.</p>
<p>Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity or mutagenicity attributable to oral administration of corticosteroids. Long-term animal studies have not been performed to evaluate the carcinogenic potential of topical corticosteroids. Studies to determine mutagenicity with hydrocortisone have revealed negative results.</p>
<p>Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. No adverse effects on male or female fertility, litter size or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet. Long-term animal studies have not been performed to evaluate the effect on fertility of topical corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b6826823-ed1e-4e32-9ab6-8b67a0f544c7"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_24bcd6f1-ddd6-46be-b41b-c5344639649b"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Teratogenic Effects:</span></span></h3>
<p class="First">Pregnancy Category C. Corticosteroids have been found to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_5235cacb-c81f-4081-b109-8d929d204085"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_c713edfc-94cd-4866-89b7-1ad220b2b907"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_9e796507-61fe-4778-923a-13697363e5e4"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. The exact incidence is not known.</p>
<p>Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <a href="#i4i_warnings_id_57e2715b-372b-48d4-9921-eb743e0c5fd8">WARNINGS</a>). More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely.</p>
<p>The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation; and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71b74b67-1e21-4d64-a365-005dca331fe8"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary Infection</span>:</h2>
<p class="First">The development of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> has occurred after use of combinations containing corticosteroids and antimicrobials. Fungal and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the cornea are particularly prone to develop coincidentally with long-term applications of a corticosteroid. The possibility of fungal invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where corticosteroid treatment has been used.</p>
<p>Local irritation on instillation has also been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_83cc472a-af69-4df0-b5cd-cda50e3a9145"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">Apply the ointment in the affected eye every 3 or 4 hours, depending on the severity of the condition.</p>
<p>Not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in <a href="#i4i_precautions_id_b978d731-fca2-4276-a41c-83e5e8efbad1">PRECAUTIONS:</a> above.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_0c5123dc-d3c7-4a2a-8f75-5c3641a5f82f"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Ophthalmic Ointment, USP is supplied in a tube with ophthalmic tip applicator in the following size:</p>
<p>3.5 g - Prod. No. 03934.</p>
<p><span class="Underline"><span class="Bold">DO NOT USE IF CAP AND NECKRING ARE NOT INTACT.</span></span></p>
<p><span class="Bold">FOR OPHTHALMIC USE ONLY</span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_8ebc390b-1b30-4b78-8891-517b8e6a90d0"></a><a name="section-9.1"></a><p></p>
<h2>Storage:</h2>
<p class="First">Store between 15° - 30°C (59°- 86°F).</p>
<p>KEEP OUT OF REACH OF CHILDREN.</p>
<p><span class="Bold">Rx only</span></p>
<p>Revised November 2007</p>
<p><span class="Bold">Bausch &amp; Lomb Incorporated</span><br>Tampa, FL 33637</p>
<p>©Bausch &amp; Lomb Incorporated</p>
<p>9113800 <span class="Bold">(Folded)</span><br>9113900 <span class="Bold">(Flat)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_dbf8f87b-5eae-42ab-a91d-faff07bb3d98"></a><a name="section-10"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure"><img alt="Cortomycin Ophthalmic Ointment (Preprinted tube 3.5 gram - Major)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c50e7f2-1208-4f19-9807-4ab0dd314d3b&amp;name=7c50e7f2-1208-4f19-9807-4ab0dd314d3b-05.jpg"></div>
<p class="First">NDC 0904-2995-38</p>
<p>Cortomycin Ophthalmic Ointment</p>
<p>Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Ophthalmic Ointment USP (Sterile)</p>
<p>Net wt. 3.5 gram</p>
<p>Rx only</p>
<p>FOR OPHTHALMIC USE ONLY.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORTOMYCIN 		
					</strong><br><span class="contentTableReg">neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0904-2995</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN SULFATE</td>
<td class="formItem">3.5 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B SULFATE</td>
<td class="formItem">10000 [USP'U]  in 1 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BACITRACIN ZINC</strong> (BACITRACIN) </td>
<td class="formItem">BACITRACIN ZINC</td>
<td class="formItem">400 [USP'U]  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0904-2995-38</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA064068</td>
<td class="formItem">10/30/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Major Pharmaceuticals
							(191427277)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Bausch &amp; Lomb Incorporated (196603781)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">807927397</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c50e7f2-1208-4f19-9807-4ab0dd314d3b</div>
<div>Set id: 7c50e7f2-1208-4f19-9807-4ab0dd314d3b</div>
<div>Version: 1</div>
<div>Effective Time: 20101104</div>
</div>
</div> <div class="DistributorName">Major Pharmaceuticals</div></p>
</body></html>
